Fasenra Receives FDA Approval for Hypereosinophilic Syndrome

Summary: The FDA just approved a new drug called Fasenra for people 12 and older with a rare blood condition called hypereosinophilic syndrome (HES). HES causes the body to make too many white blood cells, leading to painful flare-ups and extreme tiredness. In a recent study, Fasenra cut the risk of these flare-ups by 65% and significantly improved patients' energy levels. Given as a shot once every four weeks, this new treatment is a big win for patients looking to get their lives back and avoid extra hospital visits.

For more details, see rssapp-empr-com at empr.com/news/fasenra-fda-approval-hypereosinophilic-syndrome/ (opens in new tab)